louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06909448: Effect of Capacitive and Resistive Radiofrequency on Postpartum Diastasis Recti
Official title: Effect of Capacitive and Resistive Radiofrequency on Postpartum Diastasis Recti
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Diastasis Recti Abdominis (DRA)
Radiofrequency
Keywords: Diastasis recti, radiofrequency therapy, physical exercises, postpartum
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2025-04-03
Enrollment: 80
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the effect of capacitive and resistive radiofrequency on postpartum rectus abdominis diastasis.

Detailed description: Eighty females postpartum with rectus diastasis will be included in this study; they will be recruited the outpatient clinic at El Mahalla Al Kobra (The first author's pervious workplace) and will be referred by obstetric and genecology physicians. Patients will be assigned into two groups.

Group A: It will include 40 patients participating in abdominal belt. Group B: It will include 40 patients participating in abdominal belt plus TECAR therapy.

Eligibility criteria: Inclusion Criteria:

* 1. Postpartum women (7 days after delivery) having diastasis recti (separation between the two recti more than 2.5cm at the level of umbilicus).

  2. Multiparous women (2-3) times delivered vaginally with or without episiotomy.

  3. Their age will be ranged from 20 -35 years old. 4. Their BMI will be less than 30 kg/cm2.

Exclusion Criteria:

* Any participant will be excluded if she meets one or more of the following criteria:

Postpartum women will be excluded from the study if they have:

1. Abdominal or back surgery.
2. Abdominal hernia.
3. History of abnormal pregnancy, uterine fibroid or polyhydramnios during pregnancy.
4. Neurological disorders as multiple sclerosis, stroke and spinal lesion.
5. Musculoskeletal diseases such as fractures muscle strains, severe knee osteoarthritis which may affect their physical activity.

Primary outcomes:
measure: Ultrasound
timeFrame: 14 week
measure: trunk flexors strength and endurance
timeFrame: 14 week
measure: Assessment of functional status
timeFrame: 14 week
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00908648: The Use of Narrow Band Imaging in Screening Colonoscopy
Official title: The Impact of Narrow Band Imaging in Screening Colonoscopy: a Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colonoscopy
Keywords: screening colonoscopy
narrow band imaging
Lead sponsor: Valduce Hospital
Sponsor class: OTHER
First posted: 2009-05-27
Enrollment: 206
Sex: ALL
Minimum age (years): 50
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Narrow band imaging (NBI) is an imaging technique that allows a better definition of capillary pattern and improves the contrast between adenomas and the surrounding mucosa. Conflicting data exist on the ability of NBI in to improve detection of colonic neoplasm; the impact of NBI is being tested in several screening scenarios. The investigators evaluated whether the routine use of NBI, compared to white light (WL), during the withdrawal phase of screening colonoscopy improved adenoma detection.


Eligibility criteria: Inclusion Criteria:

* 50-69 year-old asymptomatic subjects at average-risk of CRC
* positive FOBT participating in a national mass-screening program and referred for colonoscopy

Exclusion Criteria:

* ongoing anticoagulation therapy
* inadequate bowel cleansing
* incomplete colonoscopy
* refusing to participate

Primary outcomes:
measure: Adenoma Detection
timeFrame: duration of colonoscopy procedure
Secondary outcomes:
measure: Detection of Flat and/or Depressed Adenomas
timeFrame: duration of colonoscopy procedure
Other outcomes:
Locations:
Study officials:
References:
citation: Machida H, Sano Y, Hamamoto Y, Muto M, Kozu T, Tajiri H, Yoshida S. Narrow-band imaging in the diagnosis of colorectal mucosal lesions: a pilot study. Endoscopy. 2004 Dec;36(12):1094-8. doi: 10.1055/s-2004-826040.
citation: Chiu HM, Chang CY, Chen CC, Lee YC, Wu MS, Lin JT, Shun CT, Wang HP. A prospective comparative study of narrow-band imaging, chromoendoscopy, and conventional colonoscopy in the diagnosis of colorectal neoplasia. Gut. 2007 Mar;56(3):373-9. doi: 10.1136/gut.2006.099614. Epub 2006 Sep 27.
Clinical trial NCT00038948: Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients
Official title: A Randomized, Open-label, Comparative Evaluation of Conversion From Calcineurin Inhibitors to Sirolimus Versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Renal Transplantation
Keywords: Renal
Allograft
Recipients
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2002-06-07
Enrollment: 830
Sex: ALL
Minimum age (years): 13
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the effect of conversion from calcineurin inhibitor to sirolimus based therapy on renal function.


Eligibility criteria: Inclusion Criteria:

* Age greater than or equal to 13 years.
* Receiving CsA or tacrolimus from the time of transplantation or within 2 weeks thereafter
* Patients with a functioning allograft and a Nankivell GFR greater than or equal to 20 mL/min, within 2 weeks before randomization

Exclusion Criteria:

* Biopsy-confirmed acute rejection within 12 weeks before randomization, that was determined to require antirejection treatment
* Patients in whom kidney-pancreas or other multiple organ transplants have been performed

Primary outcomes:
measure: Nankivell Glomerular Filtration Rate (GFR)
timeFrame: 52 weeks
Secondary outcomes:
measure: First Occurrence of Biopsy-confirmed Acute Rejection, Graft Loss, or Death.
timeFrame: 52 and 104 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor, MD
role: STUDY_DIRECTOR
References:
citation: Reichen J, Stickel F, Bhattacharya I, Matschke K, Maller E, Korth-Bradley J. Repeat-dose sirolimus pharmacokinetics and pharmacodynamics in patients with hepatic allografts. Eur J Clin Pharmacol. 2012 May;68(5):589-97. doi: 10.1007/s00228-011-1172-7. Epub 2011 Dec 6.
Clinical trial NCT05722548: Efficacy of Rectal Indomethacin in Prevention of Post-pancreatectomy Acute Pancreatitis
Official title: Efficacy of Rectal Indomethacin in Prevention of Post-pancreatectomy Acute Pancreatitis-A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Pancreatectomy
Lead sponsor: Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
First posted: 2023-02-10
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to evaluate the efficacy of rectal indomethacin in prevention of post-pancreatectomy acute pancreatitis.

Detailed description: The purpose of this study is to evaluate the efficacy of rectal indomethacin in prevention of post-pancreatectomy acute pancreatitis.

Eligibility criteria: Inclusion Criteria:

\*All patients planned to undergo pancreatectomy.

Exclusion Criteria:

* asthma
* allergic reactions to NSAIDs
* CKD
* internal hemorrhoids
* anti-platelet medications

Primary outcomes:
measure: Post-pancreatectomy Acute Pancreatitis
timeFrame: 2 weeks after pancreatectomy
Secondary outcomes:
measure: Pancreatic Fistula
timeFrame: 30 days after pancreatectomy
measure: Peripancreatic abscess
timeFrame: 30 days after pancreatectomy
measure: Length of hospital stay
timeFrame: 30 days after pancreatectomy
Other outcomes:
Locations:
Study officials:
affiliation: RenJi Hospital
name: Yingbin Liu, PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01389648: Pre-operative Physiotherapy to Prevent Post-operative Complications
Official title: The Effect of Pre-operative Chest Physiotherapy on Post-operative Complications After Major Abdominal Surgery.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Abdominal Surgery
Keywords: adult
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2011-07-08
Enrollment: 157
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to assess the roll of pre-operative chest physiotherapy, in addition to the usual care given after major abdominal surgery, in the prevention of post-operative respiratory complications.


Eligibility criteria: Inclusion Criteria:

* Major abdominal surgery

Exclusion Criteria:

* Respiratory Disease
* Pregnancy
* Mental Disease
* Dementia
* Alzheimer's Disease

Primary outcomes:
measure: respiratory complications
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam Health Care Campus
Study officials:
affiliation: Rambam Health Care Campus
name: Yoram Kluger, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00717548: Efficacy of Narrative Exposure Therapy (NET) in Treating Women After Human Trafficking or Forced Prostitution
Official title: The Effectiveness of Narrative Exposure Therapy in Treating Women After Trafficking and Forced Prostitution
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Posttraumatic Stress Disorder
Depression
Dissociation
Keywords: Somatic Complaints
Lead sponsor: University of Konstanz
Sponsor class: OTHER
First posted: 2008-07-17
Enrollment: 10
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to perform an evaluation of a trauma-focused short-term intervention (Narrative Exposure Therapy; Schauer, M., Neuner, F. \& Elbert, T.) on a variety of clinical outcome measures (PTSD, Depression, Somatic Complaints, Dissociation) in women after sexual exploitation and women trafficking.


Eligibility criteria: Inclusion Criteria:

* Sexual Exploitation or Women Trafficked or Forced Prostitution
* Symptoms of Post Traumatic Stress Disorder

Exclusion Criteria:

* Current Psychotic Symptoms

Primary outcomes:
measure: PTSD, Depression, Somatic Complaints, Dissociation
timeFrame: Pre-Test, 4-weeks-Post-Test, 6-months-follow-up
Secondary outcomes:
Other outcomes:
Locations:
city: Konstanz
country: Germany
facility: Research and Psychological Outpatient Clinic, University of Konstanz, Center for Psychiatry, House 22
Study officials:
References:
Clinical trial NCT00482248: Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma
Official title: An Open-label Extension Study to Assess Long Term Safety and Tolerability of Omalizumab Treatment in Adults and Adolescents With Severe Allergic Asthma Who Participated in the 52 Week CIGE250011E2 Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Asthma
Keywords: Asthma
anti-immunoglobulin E
omalizumab
allergic asthma
Lead sponsor: Novartis
Sponsor class: INDUSTRY
Collaborators: name: Genentech, Inc.
First posted: 2007-06-05
Enrollment: 132
Sex: ALL
Minimum age (years): 12
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will assess further the safety and tolerability of long-term treatment with omalizumab by extending omalizumab treatment by 1 year for those patients with allergic asthma who successfully completed study CIGE25011E2.


Eligibility criteria: Inclusion Criteria:

* Patients with a history of severe allergic asthma who completed the treatment period of CIGE250011E3 protocol, without experiencing any significant drug-related adverse events
* Male or female patients 12-75 years of age who have given written informed consent approved by the ethical committee

Exclusion Criteria:

* Patients who had not received study medication for greater than 84 days since visit 38 of study CIGE240011E3
* Pregnant females or nursing mothers
* Patients with know hypersensitivity to any ingredients of Omalizumab or related drugs

Other protocol-defined inclusion/exclusion criteria may apply

Primary outcomes:
measure: Safety assessed by adverse events, serious adverse events, hematology, blood chemistry and urinalysis value, vital signs data, the performance of physical examinations and body weight measurements.
Secondary outcomes:
measure: Efficacy assessed by changes in forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC), the investigator's assessment of asthma control, corticosteroid use, the incidence of hospitalization and outpatients visits, and absenteeism fr
Other outcomes:
Locations:
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_CHAIR
References:
Clinical trial NCT01236248: Drug Abuse Prevention Among Girls Through a Mother-Daughter Intervention
Official title: Drug Abuse Prevention Among Girls Through a Mother-Daughter Intervention
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Substance Use
Keywords: drugs
youth
parent
computer
prevention
Lead sponsor: Columbia University
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2010-11-07
Enrollment: 916
Sex: FEMALE
Minimum age (years): 11
Maximum age (years): 13
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine a computer- and family-based drug abuse prevention program is able to reduce drug use among early adolescent girls.

Detailed description: This study longitudinally tested a computerized, parent-involvement substance abuse prevention program for adolescent girls and their mothers. The prevention program aimed to strengthen and sustain the mother-daughter bond while equipping girls with the necessary information and skills to increase protective factors and reduce risk factors associated with tobacco, alcohol, and other harmful substance use.

Eligibility criteria: Inclusion Criteria:

* English-speaking New York City (NYC) area girls
* Ages 11 - 13 years
* Must have private access to a computer with high-speed connectivity

Exclusion Criteria:

* Non-English-speaking girls who do not live in the NYC area
* Younger than 11 or older than 13 years of age
* Those who lack of private access to a computer with high-speed connectivity

Primary outcomes:
measure: Rate of Substance Use
timeFrame: Annually
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Columbia University
state: New York
Study officials:
affiliation: Columbia University
name: Steven P Schinke, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00249548: Low-Cost Contingency Management for Hispanic Outpatients - 3
Official title: Low-Cost Contingency Management for Hispanic Outpatients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Substance Abuse
Keywords: contingency management
substance abuse
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
Collaborators: name: UConn Health
First posted: 2005-11-07
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effectiveness of a lower-cost contingency management (CM) procedure in Hispanic substance abusing outpatients. Thirty individuals meeting DSM-IV criteria for substance dependence receive one of two conditions: (a) standard treatment, or (b) standard treatment plus prize CM. Using a cross-over design, CM is implemented in a community-based outpatient clinic and compared with non-CM in the same clinic. The participating clinic is randomly assigned to receive either the CM or non-CM phase first; 15 weeks after the final participant in one phase is enrolled, a one-week washout period occurs, followed by a switch to the other phase. Patients initiating outpatient treatment during the non-CM phase receive standard treatment and submit urine and breath samples 2/week during Weeks 1-6 and 1/week during Weeks 7-12. Patients initiating treatment during the CM phase also receive standard treatment and the same breath and urine monitoring. In addition, they earn the opportunity to win prizes for coming to treatment and for submitting negative breath and urine samples. Follow-up interviews are conducted at 1,3,6 and 9 months following intake during which substance use and psychosocial functioning are assessed.


Eligibility criteria: Inclusion criteria:

* age \> 18 years
* current DSM-IV substance dependence.

Exclusion criteria:

* have a serious, uncontrolled psychiatric illness (e.g., acute schizophrenia, bipolar disorder, severe or psychotic major depression, or suicide risk) on the basis of history or medical examination
* have dementia (\<23 on the Mini Mental State Exam; Folstein et al. 1975)
* DSM-IV diagnosis of pathological gambling
* plans to move from the Hartford are within 9 months.

Primary outcomes:
measure: Drug use
timeFrame: baseline and each follow-up
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: UConn Health
name: Nancy Petry, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02065648: Syngo NATIVE Contrast Enhanced 3D MRA on 3T Verio Magnet
Official title: NATIVE Sequence for Non-Contrast MR Angiogram Compared With Conventional Contrast Enhanced 3D MRA on 3T Verio Magnet
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Vascular Disease
Keywords: MRA
Syngo Native
Gadolinium
Non contrast
Lead sponsor: Cedars-Sinai Medical Center
Sponsor class: OTHER
Collaborators: name: Siemens Corporation, Corporate Technology
First posted: 2014-02-19
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Consenting patients referred for standard of care contrast-enhanced abdominal MR Angiography

Brief summary: The purpose of the study is to compare non-contrast abdominal MR Angiogram (MRA) syngo NATIVE sequence performed on a 3T Verio Siemens magnet to a standard contrast-enhanced MRA performed as part of routine clinical care in patients with normal renal function to determine if the non-contrast NATIVE sequence is a viable alternative to contrast enhanced MRA in patients with renal insufficiency. There are no interventions--this is an observational study.

Detailed description: If the NATIVE sequence proves to be a viable alternative to contrast enhanced MRA it will provide imaging physicians with the diagnostic tool to assess vascular disease in patients with renal insufficiency without placing them at risk for additional co-morbidities.

Eligibility criteria: Inclusion Criteria:

Over age 18 Signed informed consent Referred for standard of care MRA

Exclusion Criteria:

No contra-indications for MRI/MRA ie implants which could interfere with magnets Renal insufficiency which would preclude use of contrast-enhanced contrast for a standard of care MRA

Primary outcomes:
measure: Effectiveness of non-contrast enhanced MRA sequence
timeFrame: 36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Cedars-Sinai Medical Center
state: California
Study officials:
affiliation: Cedars-Sinai Medical Center
name: Rola Saouaf, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Cedars-Sinai Medical Center
name: Franklin G. Moser, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03260348: Acute Respiratory Distress Syndrome in Taiwan
Official title: Epidemiology and Long-term Outcomes of Patients With Acute Respiratory Distress Syndrome in Taiwan
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Respiratory Distress Syndrome
Lead sponsor: Chang Gung Memorial Hospital
Sponsor class: OTHER
First posted: 2017-08-24
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients in medical intensive care unit during study period.

Brief summary: The study enrolls ARDS patients in medical ICUs in 11 Hospitals in Taiwan. The epidemiology and long-term outcomes of the patients will be recorded.


Eligibility criteria: Inclusion Criteria:

* Age \>18 years
* Patients in medical intensive care unit in Sep., 2017 and Jan., 2018.

Exclusion Criteria:

* Age less than 18 years.
* Pregnancy.

Primary outcomes:
measure: Epidemiology
timeFrame: two months
measure: Mortality
timeFrame: 90 days
measure: Long-term outcome
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Chang Gung Memorial Hospital
name: Kuo-Chin Kao
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01138748: Prediction of the Effectiveness of Hypofractionated Radiation Therapy in Early Stage Lung Cancer by Bio-imaging and Biomarkers
Official title: Prediction of the Effectiveness of Hypofractionated Radiation Therapy in Early Stage Lung Cancer by Bio-imaging and Biomarkers
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Inoperable Early Stage Non-small Cell Lung Cancer
Keywords: inoperable early stage non-small cell lung cancer
radiation therapy
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
Collaborators: name: Nationaal Kankerplan
First posted: 2010-06-07
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Surgical resection with mediastinal lymph node sampling is currently the therapy of choice for early stage (I-II) non-small cell lung cancer (NSCLC). Selected patients unwilling or unable to tolerate surgery are referred for so-called 'curative' high dose radiotherapy. This has shown to result in a long term local disease control rate and a high cancer specific survival.

The current trial addresses the issue if progression free survival (PFS) in patients treated with radiotherapy can be predicted by a multi-variate model derived from a composite of bio-imaging and biomarkers


Eligibility criteria: Inclusion Criteria:

* Proof of cT1a/b - 2a/b N0M0 NSCLC
* Informed Consent signed
* Resectable tumour
* \> 18 years old
* men and women

Primary outcomes:
measure: development and validation of a multi-variate predictive model
timeFrame: from 2 to 5 years
Secondary outcomes:
measure: the clinical response and complication rate
timeFrame: from 2 to 5 years
measure: local, regional or distant failure
timeFrame: from 2 to 5 years
measure: progression free survival
timeFrame: from 2 to 5 years
measure: disease specific overall survival
timeFrame: from 2 to 5 years
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: University Hospital Ghent
Study officials:
affiliation: University Hospital, Ghent
name: Jan Van Meerbeeck, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References: